Low IL-1β expression correlates with improved OS in EGFR- and ALK-altered tumors, suggesting that IL-1β expression can inform both prognosis and therapeutic strategies in NSCLC, including IL-1β-targeted approaches in precision medicine. This evidence concerns the gene EGFR and non-small cell lung carcinoma.